The Global Health Body Sounds Alert Over Critical Shortage of Obesity Medications
Fewer than 10% of individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, warns the global health agency as it publishes its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
According to estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the treatments that can assist patients in reducing significant weight, explains the agency.
Skinny Jab Supply Crisis
Even under the present most optimistic scenario, the supply of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, per the health organization.
The advice encourages governments and firms to increase availability, by measures like licensing agreements.
The intellectual property rights on a key compound – the main component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so users reduce food intake.
Individuals typically see weight reduction in the initial weeks of commencing the regular doses.
Studies indicates patients may put most of the weight back on within a year of discontinuing the drug, as their usual appetite resume.
Being carrying excess weight raises your likelihood for developing health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
